EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) – Epidemiology Forecast to 2024 market research report is the latest addition to RnRMarketResearch.com and its collection of therapeutics business intelligence reports aimed to help take better decisions.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists forecast that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate (AGR) of 1.09%. The number of hospitalized incident cases of MRSA in the US, France, Italy, Spain, UK, and Japan will increase, with AGRs ranging from 0.14% (Italy) to 3.54% (Japan), but will decrease in Germany, with a negative AGR of 0.19%.

Research, epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, such as methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections (unspecified site) is A49.02.

Complete report on 2015 market outlook of “Methicillin-Resistant Staphylococcus Aureus” addition with 12 market data tables and 08 figures, spread across 62 pages is http://www.rnrmarketresearch.com/epicast-report-methicillin-resistant-staphylococcus-aureus-mrsa-epidemiology-forecast-to-2024-market-report.html .

Scope:

• The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.
• The MRSA epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Request for sample:
http://www.rnrmarketresearch.com/contacts/request-sample?rname=437236 . This is a premium report price at US$3995 for a single user PDF license)

Reasons to buy:

• Develop business strategies by understanding the trends shaping and driving the global MRSA market.
• Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
• Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.

Explore More Research Report on Infectious Diseases therapeutics Market.

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.